Thursday, November 13, 2025 8:44:22 AM
11m warrants at .91 looks like .. the Investors will be $0.9116 per Share (or $0.9115 per Pre-Funded Warrant in lieu of Shares). The first closing of the Private Placement is expected to occur the week of November 17, 2025 (the “First Closing”). At the First Closing, subject to customary closing conditions set forth in the Securities Purchase Agreement, the Company expects to issue and sell 1,964,905 Shares (or Pre-Funded Warrants in lieu of Shares).The second closing of the Private Placement (the “Second Closing”) is subject to stockholder approval (the “Stockholder Approval”) in accordance with the rules of the NYSE American, consummation of the Exchange (defined below) contemplated by the Term Sheet (defined below) with Daewoong (defined below), and other customary closing conditions set forth in the Securities Purchase Agreement. At the Second Closing, the Company expects to issue and sell 4,616,924 Shares (or Pre-Funded Warrants in lieu of Shares) and 6,581,829 Warrants....
Recent AEON News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 09:20:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 09:19:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 09:18:34 PM
- AEON Biopharma Sets Annual Shareholder Meeting • GlobeNewswire Inc. • 04/24/2026 08:05:00 PM
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 • GlobeNewswire Inc. • 04/03/2026 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:14 PM
- AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards • GlobeNewswire Inc. • 04/03/2026 08:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:36:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:32 PM
- AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program • GlobeNewswire Inc. • 03/30/2026 08:05:00 PM
- AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program • GlobeNewswire Inc. • 03/25/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 12:13:33 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 08:05:20 PM
- AEON Biopharma Appoints John Bencich as Chief Financial Officer • GlobeNewswire Inc. • 03/09/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:07:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:06:25 PM
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting • GlobeNewswire Inc. • 03/05/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 01:40:27 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/18/2026 09:05:27 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 09:38:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 09:06:10 PM
- AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions • GlobeNewswire Inc. • 01/21/2026 09:05:00 PM
